Akeso Valuation Multiples

Akeso Overview

About Akeso

Akeso Inc is an investment holding company. The Company's subsidiaries were involved in research and development, production, and commercialization of biopharmaceutical products. The company currently has a pipeline of over 30 drugs for the treatment of diseases like cancers, autoimmune diseases, inflammation, and metabolic diseases, 17 of which have entered the clinical stage, including two first-in-class bi-specific antibody drugs (PD-1/CTLA-4 and PD-1/VEGF). The majority of the company's revenue is earned in Mainland China, and also has its presence in USA and Other regions.

Founded

2019

HQ

Employees

3.0K

Website

akesobio.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $534M

EBITDA: ($44M)

EV

$17B

Valuation Multiples

Multiples.vc

Start free trial

Akeso Financials

Akeso reported last 12-month revenue of $534M and negative EBITDA of ($44M).

In the same LTM period, Akeso generated $433M in gross profit, ($44M) in EBITDA losses, and had net loss of ($107M).

Akeso P&L

In the most recent fiscal year, Akeso reported revenue of $311M and EBITDA of ($35M).

Akeso expects next 12-month revenue of XXX and NTM EBITDA of XXX

Akeso Stock Performance

Akeso has current market cap of $18B, and enterprise value of $17B.

Akeso's stock price is $19.30.

Akeso Valuation Multiples

Akeso trades at 32.6x EV/Revenue multiple, and (397.3x) EV/EBITDA.

Akeso Financial Valuation Multiples

As of April 18, 2026, Akeso has market cap of $18B and EV of $17B.

Equity research analysts estimate Akeso's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Akeso has a P/E ratio of (166.5x).

Akeso Margins & Growth Rates

Akeso's revenue in the last 12 month grew by 61%.

Akeso's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Akeso's rule of 40 is 82% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Akeso's rule of X is 187% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Akeso Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Akeso M&A Activity

Akeso acquired XXX companies to date.

Last acquisition by Akeso was on XXXXXXXX, XXXXX. Akeso acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Akeso Investment Activity

Akeso invested in XXX companies to date.

Akeso made its latest investment on XXXXXXXX, XXXXX. Akeso invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).